HCV antiviral drugs have the potential to adversely perturb the maternal-fetal communication axis through inhibition of CYP3A7 DHEA-S oxidation
The hepatitis C virus (HCV) poses a great risk to pregnant people and their developing fetus, yet no…
The focus of research in the Lampe lab is understanding the role of drug metabolism and pharmacokinetics (DMPK) in drug efficacy within special population groups, with a particular emphasis on cytochrome P450 enzymes (CYP). Studies based on in vitro, structural, and computational models are used to gain more insight as to how neonates metabolize HIV drugs and the importance of CYP3A ontogeny in the liver. Research on how CYP polymorphisms in African Americans can lead to different pharmacokinetic and pharmacodynamic (PKPD) effects of certain antipsychotic drugs is also an area of active investigation in the laboratory. A third project is focused on studying the role of the ‘pathobiome’ in drug metabolism, particularly in cystic fibrosis patients. Lastly, the molecular mechanisms that underlie reproductive, developmental, and immunological toxicities in populations exposed to high levels of the man-made per- and polyfluoroalkyl substances (PFAS) is another research project area.
This research project involves functional and computational modeling of HIV drug metabolism in the neonatal liver to accurately predict drug metabolism and disposition in the neonate and developing infant. Data generated from in vitro studies using CYP3A7 recombinant enzyme, a neonatal specific CYP isoform, and neonatal human liver microsomes are being modeled to define the QSAR of CYP3A7-mediated metabolism of HIV inhibitors and to build a PBPK model for the neonatal disposition and DDI risk of these HIV drugs using the GastroPlus® software package.
CYP3A7 Crystal structure 3D flyby
PFAS, the “forever chemicals”, are associated with a wide variety of illnesses (hyperlipidemias, cancer, immunotoxicity, hepatotoxicity and developmental defects). The molecular mechanisms related to PFAS toxicities are not well understood. Via a collaboration with Dr. Rebecca McCullough, changes in oxylipin production and in inflammatory signals after PFAS exposure are being investigated as part of the hepatic response to these ubiquitous environmental contaminants.
Little is known about the impact of the “pathobiome” on drug metabolism and disposition. During an infection, the pathogen is often the most abundant bacterial species present in the host and it has the potential to make a substantial contribution to the local metabolism and clearance of drugs. Our research goal is to study the ability of Pseudomonas aeruginosa, an important opportunistic pathogen of the lung in cystic fibrosis patients, to metabolize drugs and to understand how cytochrome P450 enzymes may contribute to this process.
The hepatitis C virus (HCV) poses a great risk to pregnant people and their developing fetus, yet no…
J Biol Chem. 2023 Sep 30;299(10):105283. doi: 10.1016/j.jbc.2023.105283. Online ahead of print. NO A…
Idiosyncratic drug reactions (IDRs) in their most deleterious form can lead to serious medical compl…
J Biol Chem. 2023 Jun 29:104993. doi: 10.1016/j.jbc.2023.104993. Online ahead of print. ABSTRACT Hum…
Commun Biol. 2023 Jun 2;6(1):597. doi: 10.1038/s42003-023-04964-2. ABSTRACT Burn induces a systemic …
Per- and polyfluoroalkyl substances (PFAS) are a chemical class of highly stable, fluorinated compou…
By understanding the differences in DMPK between the general adult population and understudied patient groups like neonates or African Americans, we are hoping in the long term to improve drug treatment which will lead to a better quality of care for these patients. We expect that our research will contribute to new and critical knowledge on drug therapy at the developmental, genetic and disease levels.
Jed
Principal Investigator, Ph.D.
Principal Investigator
Research Instructor
Ph.D. Student
Ph.D. Student
Ph.D. Student
Welcoming to 2 new lab members, Julieta Torres (Undergraduate student) and Abhinav Pentyala (Master …
On October 4th, 2023. Dr. Lampe presented a seminar in the Department of Pharmacology and Molecular …
On September 29th, 2023. Dr. Lampe hosted the 2023 Annual Meeting of the Rocky Mountain Discussion g…
On September 25th, 2023. Dr. Lampe presented a talk at the ASPET Focus on Pharmacology series: Advan…
On July 8-9, 2023. Hannah Work presented a poster on her research work on HCV inhibitors.
On May 18-21, 2023. The LAMPE Lab presented several of their research works in poster or talk format…
In May 2023, Dr. Lampe was asked by Prof. Fred Guengerich to organize the 2027 International Confere…
In April 2023, Dr. Lampe was invited to join the International Society for the Study of Xenobiotics …
On February 7th, 2023. Dr. Lampe gave a presentation in the Department of Pharmacology at Dalhousie …
On August 29-30, 2022, Michaela Hvizdak, the newest addition to the Lampe Lab, presented her researc…
Skaggs School of Pharmacy & Pharmaceutical Sciences
Anschutz Medical Campus
12850 E Montview Blvd,
Aurora, CO 80045
Pharmacy & Pharmaceutical
Sciences Building (V20)
Second floor | Room 2108